(Q36883321)

16 August 2017

Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients (English)

1 reference

16 August 2017

1 reference

Murray D Krahn

5

0 references

author name string

Maciej Witkos

1

1 reference

16 August 2017

Qi-Long Yi

2

1 reference

16 August 2017

Jenny Heathcote

3

1 reference

16 August 2017

Moira K Kapral

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Canadian Journal of Gastroenterology

16 August 2017

0 references

volume

20

1 reference

16 August 2017

2

1 reference

16 August 2017

107-111

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

16 August 2017

start time

1 January 2006

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Hepatitis C treatment eligibility in an urban population with and without HIV coinfection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Hepatitis C and human immunodeficiency virus infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Diagnosis and 10-year follow-up of a community-based hepatitis C cohort.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Hepatitis C in HIV-infected patients--therapeutic approach

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Prediction of hepatitis C burden in Canada

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Management of chronic hepatitis C: clinical audit of biopsy based management algorithm

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

How far is it to the nearest hospital? Calculating distances using the Statistics Canada Postal Code Conversion File

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Medical practices regarding hepatitis C virus infection in Europe

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Management of viral hepatitis: clinical and public health perspectives--a consensus statement. CASL Hepatitis Consensus Group. Canadian Association for Study of the Liver

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Modalities of care in anti HCV positive patients identified in General Medicine in the Alpes-Maritimes district

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538973

Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16482237

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16482237

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The hepatitis C prevention, support and research program: Health Canada initiatives on hepatitis C. Health Canada

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16482237

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2006/638272

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

16482237

1 reference